Drug maker Rohto plans clinical trials in Hong Kong as OASES’ first Japan partner

Top university research, cross-border data exchanges and access to mainland China’s large market have attracted Japanese firm Rohto Pharmaceutical to conduct clinical trials in Hong Kong, making it the first company from the country to partner with the city’s government under a flagship investment initiative. Rohto,…

Opens the original publisher in a new tab. Full articles belong to their publishers; a subscription may be required.